Emodin Attenuated the Kidney Damage of High-Fat-Diet Mice via the Upregulation of Glucagon-Like Peptide-1 Receptor

Jinlei Liu, Yao Sun, Hongwei Zheng, Jing Wang, Lili Liu, Bing Song, and Haoqiang Zhang

1First Affiliated Hospital of Jinzhou Medical University, Jinzhou, China
2Department of Pharmacy, Taikang Xianlin Drum Tower Hospital, Medical School of Nanjing University, Nanjing, China
3Department of Endocrinology, Affiliated Zhongda Hospital of Southeast University, Nanjing, China

Correspondence should be addressed to Bing Song; songbing1978@163.com and Haoqiang Zhang; hk_zhang_1991@163.com

Received 15 December 2020; Revised 24 April 2021; Accepted 6 May 2021; Published 1 June 2021

Objective. Secretion of glucagon-like peptide 1 (GLP-1) and its effect on target organs were impaired in individuals with obesity. However, its mechanism needs to be further studied. We aim to explore the roles of the receptor of GLP-1 (GLP-1R) involved in high-fat-diet- (HFD-) induced kidney damage improved by emodin.

Methods. Male C57bl/6 mice were fed with HFD diet and therapied by emodin. NRK-52E cells were cultured and treated with palmitic acid or low-density lipoprotein cholesterol (LDL-C). Emodin was used to remedy the NRK-52E cell damage. GW9662 was administrated to block the function of peroxisome proliferator-activated receptor γ (PPAR-γ). GLP-1 in the plasma was measured by ELISA. PPAR-γ and GLP-1R in the kidney and NRK-52E cells were detected by western blotting. The interaction between PPAR-γ protein and GLP-1R promoter regions was observed by chromatin immunoprecipitation (ChIP).

Results. Postprandial GLP-1 levels in plasma, as well as PPAR-γ and GLP-1R, decreased in kidney tissue of HFD mice, while they were reserved by emodin treatment. Although PPAR-γ and GLP-1R were not downregulated by LDL-C, they were suppressed by palmitic acid. Interestingly, GLP-1R mRNA was detected by PCR in the mixture pulled down with PPAR-γ antibody. Additionally, downregulation of PPAR-γ and GLP-1R by palmitic acid was remanded by emodin. Moreover, GW9662, an inhibitor of PPAR-γ, abolished the protective effect of emodin.

Conclusion. The kidney damage of HFD mice seems to be alleviated by emodin via the upregulation of GLP-1R in kidney tissue.

1. Introduction

In recent years, the prevalence of obesity [1–3] and diabetes [4, 5] is increasing. Their damages of target organs (including kidney) have become urgent problems. Although diabetic nephropathy is one of the most important causes of end-stage renal disease [6, 7], relatively few studies have been done on obesity-related glomerulopathy for its insidious development [8].

A few studies suggested that obesity damages the kidney of animals and human beings and even results in end-stage kidney disease. However, its mechanism remains unclear [9]. Previous studies have found that the kidney is also rich insulin receptor [10] except the typical insulin-targeted organs: fat, muscle, and liver. Recent work found that insulin resistance is involved in kidney injury in mice induced by HFD [11].

Emodin is a kind of anthraquinone with biological activity extracted from the roots and stems of rhubarb and other Chinese herbal medicines. It has antibacterial, anti-inflammatory, antilucer, antitumor, regulatory immunity, and antidiabetes effects [12]. Our previous study found that emodin can alleviate insulin resistance in KKAy mice with diabetes [13]. The mechanisms of emodin in diabetic nephropathy have been widely studied. In addition, it has been found that emodin can improve insulin resistance of diabetic mice through PPAR-γ [14, 15]. Moreover, PPAR-γ is one of the most important targets [16] involved not only in diabetic nephropathy [17] but also in obesity-related glomerulopathy [15]. However, the protective effect of emodin activated PPAR-γ...
involved in obesity-related glomerulopathy still needs to be further studied.

GLP-1 is a polypeptide secreted by L-type cells of the intestinal epithelium, which can stimulate insulin secretion and inhibit glucagon secretion. Therefore, it plays an important role in blood glucose homeostasis [18]. GLP-1 agonists bind to GLP-1R on target organs [19, 20]. It has been found that the expression of GLP-1R decreased in the kidney of HFD mice [21]. Therefore, we guess that the dysfunction of GLP-1R signaling pathway may be one of the reasons of kidney damage in obese mice induced by HFD. Although PPAR-γ and GLP-1R are both involved in renal injury of obese or diabetic animal models [22–25], the relationship between PPAR-γ and GLP-1R is unknown. In other words, as a nuclear receptor, the regulation effect of PPAR-γ on the expression of GLP-1R needs to be further explored. Additionally, emodin may regulate GLP-1R via PPAR-γ.

To confirm our hypothesis, we fed mice with HFD, and then, emodin treatment was given to detect the regulatory effect of emodin on GLP-1R and PPAR-γ in the kidney of mice with HFD. Moreover, NRK-52E cells were cultured and stimulated by LDL-C or palmitic acid and then remedied with emodin. Finally, GW9662 administration and ChIP assays were performed to confirm the role of PPAR-γ involved in GLP-1R expression.

2. Methods

2.1. Experimental Animal Housing and Treatment. Healthy C57BL/6J mice (male, age 7 weeks, n = 40) were purchased from HFK Bioscience Co., Ltd. (Beijing, China). All mice were housed in the specified pathogens free for 1 week before experiments. Animals were randomly divided into 4 groups according to their diets and treatments: normal chow group (NC, n = 10), HFD group (HFD, n = 10), emodin treatment group (EM, n = 10), and HFD group with emodin (EM-HFD, n = 10). 2 animals in the HFD group and 1 in the HFD-EM group were detected with hyperglycemia. Additionally, 1 mouse in the HFD-EM group died in the intragastric administration. So, we excluded 4 mice in the NC group (2 mice) and EM group (2 mice). After 12 weeks of feeding with normal chow or HFD diet, mice were administrated with emodin (in DMSO) (50 mg/kg) [13] (cat no. 518-82-1; Solarbio Science & Technology Co., Ltd., Beijing, China) or bacteria-free water of the same frequency and the same volume every other day for 6 weeks (Figure 1(a)). Body weights were measured weekly. All experiments were performed according to the guidance of the Ethics Committee for Experimental Research from the First Affiliated Hospital of Jinzhou Medical University.

2.2. Assays on Blood and Urine. At the end of the experiment, mice were sacrificed by cervical dislocation. Blood samples were collected to measure the levels of fasting plasma glucose (FPG), fasting serum insulin (FSI), serum creatinine (Scr), blood urea nitrogen (BUN), total cholesterol (TC), low-density lipoprotein cholesterol (LDL-C), and free fatty acids (FFA).

2.3. Measurement of Serum GLP-1. After 8 hours of fasting and 30 minutes of glucose gavage (2 g/kg), blood samples were taken from the heart, centrifuged at 1200 rpm (4°C) for 5 min. After the supernatant was obtained, the level of GLP-1 in serum was detected by an ELISA kit (intrassay precisions CV% < 8% and CV% < 10%) form CUSABIO Technology LLC (CUSABIO, Wuhan, China, Catalogue No.: CSB-E08118m).

2.4. NRK-52E Cell Culture and Treatment. The NRK-52E cells were obtained from American Type Culture Collection (Manassas, VA, USA). Cells were cultured in Dulbecco’s modified Eagle’s medium F-12 supplemented with 10% fetal bovine serum, penicillin (100 U/ml), and streptomycin (100 μg/ml) in an incubator at 37°C with 5% CO2. NRK-52E cells were treated with LDL-C (100 or 200 μg/ml) [26] or palmitic acid (150 μM) [27] for 24 h. And then, NRK-52E
cells with 150 μM palmitic acid were treated with emodin (50 μM) [12, 28] and GW9662 (25 μM) [29] at the time point of palmitic acid treatment.

2.5. Masson Staining. Tissues from the upper pole of the kidney were collected from freshly sacrificed mice and fixed with 4% paraformaldehyde for 72 h before paraaffin sections (5 μm) were obtained. Masson staining was conducted according to the manufacturer’s protocol (Wanlei Biotechnology Co. Ltd, Shenyang, China, Catalogue No.: WLA045) similar to our previous study [30].

2.6. Western Blotting. Western blotting was carried out according to our previously described protocol [31] and described briefly as follows. Kidney tissue or NRK-52E cells were extracted by radioimmunoprecipitation (RIPA) (Wanlei Biotechnology Co. Ltd, Shenyang, China, Catalogue No.: WLA016a) and measured by a BCA assay according to the manufacturer’s instructions (Wanlei Biotechnology Co. Ltd, Shenyang, China, Catalogue No.: WL01845). Proteins were separated in SDS-PAGE gels and transferred to polyvinylidene fluoride (PVDF) membranes. Rabbit-anti-mouse primary antibodies were used to bind target proteins including PPAR-γ (Santa Cruz Biotechnology, Inc., Dallas, Texas, USA, Catalogue No.: sc-390740), GLP-1R (Bioss, Beijing, China, Catalogue No.: bs-1559R), and β-actin (Wanlei biotechnology co. Ltd, Shenyang, China, Catalogue No.: WL01845) at 4°C overnight. And then, goat-anti-rabbit secondary antibody conjugated with HRP (Wanlei Biotechnology Co. Ltd, Shenyang, China, Catalogue No.: WLA023a) incubation was performed for binding primary antibodies. The ECL kit (Wanlei Biotechnology Co. Ltd, Shenyang, China, Catalogue No.: WLA006a) was utilized before exposure to detect the protein levels.

2.7. ChIP. The ChIP assay was conducted according to the protocol from the manufacturer (Wanlei Biotechnology Co. Ltd, Shenyang, China, Catalogue No.: WLA122). NRK-52E cells were cross-linked by 1% formaldehyde for 10 min at room temperature. After ultrasonic splintering, chromatin solutions were incubated with 4 μg of anti-PPAR-γ antibody

Figure 2: Indexes of glucose or lipid metabolism and renal function of mice. (a–h) “∗” shows indexes of the HFD group or EM group vs. the NC group, p < 0.05; “#” shows indexes of EM-HFD group vs. HFD group, p < 0.05. n = 8 in each group.
or with IgG and rotated overnight at 4°C. Complexes were collected with protein A Sepharose beads for 1 h at 4°C. To purify the immunoprecipitated DNA, beads were treated with DNase-free RNase A and proteinase K. And then, DNA was resuspended in distilled water. To amplify the GLP-1R promoter regions containing PPAR-γ, 5′-CAAGTCCACGCTGACACTC-3′ and 5′-GCTCTGTAAACAGCTTGATGAA-3′ were used as forward and reverse primers, respectively [32]. After amplification, PCR products were analyzed on a 2% agarose gel. For quantification of the ChIP assay, input genomic DNA and immunoprecipitated DNA were amplified by real-time PCR.

2.8. Statistical Analysis. All data were described as mean ± standard deviation. Statistical differences were determined by using Student’s t-test and one-way ANOVA followed by LSD for multiple comparison test. Data were analysis by SPSS 22.0 (SPSS Inc., Chicago, IL, USA). p < 0.05 was considered a significant difference.

3. Results

3.1. Effect of Emodin on Body Weights. To explore the effect of emodin on body weight of mice with HFD, all mice (8 weeks old) were fed with common chow or HFD for 12 weeks. And then, part mice with common chow or HFD were treated with emodin for 6 weeks (Figure 1(a)). Compared to mice with common chow, body weights of mice increased 24.89% after 12 weeks feeding with HFD. At that time, emodin was used to treat HFD-induced mice with obesity. Interestingly, compared to mice without emodin, emodin prevented body weights increasing from HFD by 8.70% after 6 weeks of emodin treatment (Figure 1(b)).

3.2. Effect of Emodin on Biochemical Indexes of Blood and Urine. In order to detect the effect of emodin on homeostasis of glucose and lipid metabolism, FPG, FSI, TC, LDL-C, and FFA were measured. Amazingly, emodin not only decreased the levels of FPG and FSI increased by HFD but also decreased the levels of TC, LDL-C, and FFA elevated in HFD feeding mice (Figures 2(a)–2(e)). For the best exploration of kidney damage alleviated by emodin, Scr, BUN, and urine albumin/creatinine were measured. Although Scr and BUN levels were not increased by HFD, BUN levels were decreased by emodin in mice with or without HFD (Figures 2(f) and 2(g)). Moreover, HFD elevated the levels of albumin/creatinine, while they were decreased by emodin (Figure 2(h)).

3.3. Effect of Emodin on GLP-1 in Serum and Pathology in the Kidney. Although no significant change of fasting GLP-1 was detected in mice with or with HFD (Figure 3(a)), compared
with mice administrated with sterile water, the levels of GLP-1 in mice with common chow increased more than 2-folds after glucose intragastric administration for 30 minutes. Additionally, GLP-1 levels after glucose intragastric administration in mice with common chow are lower than those with HFD. However, they were improved by emodin administration (Figure 3(b)). In Masson stain of renal tissue, more collagen fibers were deposited in the glomeruli of mice fed with HFD. Interestingly, the deposited collagen was decreased by emodin (Figure 3(c)).

3.4. Effects of Emodin on GLP-1R and PPAR-γ in Renal of Mice with HFD. Owing to the levels of GLP-1 levels after administrated with glucose were decreased by HFD and increased by emodin, GLP-1R levels of mice with or without HFD (emodin) were measured. Kidney tissue of mice with HFD showed downregulated GLP-1R levels, compared with those of mice with common chow. Moreover, GLP-1R levels were upregulated by emodin (Figure 4(b)). In addition, PPAR-γ, one of the most important targets of emodin, was detected. Undoubtedly, PPAR-γ levels decreased in the kidney of mice with HFD and increased by emodin (Figure 4(a)).

3.5. LDL-C Did Not Influence the Levels of GLP-1R or PPAR-γ in NRK-52E Cells. To further explore the mechanism of kidney damages, especially for the damage of renal tubules, NRK-52E cells were cultured and treated with LDL-C or palmitic acid. Although LDL-C levels are significantly increased in mice with HFD, in this present study, LDL-C treatment did not change the levels of GLP-1R or PPAR-γ in NRK-52E cells at the concentration of 100 μg/ml or 200 μg/ml (Figures 4(c) and 4(d)).

3.6. Effects on GLP-1R or PPAR-γ in NRK-52E Cells of Palmitic Acid and Emodin. Although LDL-C did not suppress the levels of GLP-1R or PPAR-γ in NRK-52E cells, palmitic acid significantly downregulated the levels of GLP-1R or PPAR-γ in NRK-52E cells at the concentration of 150 μM (Figures 5(a) and 5(b)). However, the downregulation of GLP-1R or PPAR-γ was restored by emodin at the concentration of 50 μM (Figures 5(c) and 5(d)).

3.7. Interactions between PPAR-γ and GLP-1R. The expression of GLP-1R needs the transcription and translation of GLP-1R gene. To uncover the interaction between PPAR-γ
and GLP-1R, ChIP assay was carried out. GLP-1R promoter sequence was observed by real-time PCR in the immunoprecipitated DNA (Figure 5(e)). To further explore the regulation of PPAR-γ to GLP-1R, GW9662, a specific PPAR-γ inhibitor, was used to treat NRK-52E cells with palmitic acid and emodin. Interestingly, elevated GLP-1R levels were suppressed by GW9662 (Figure 5(f)).

4. Discussion

The renal damage is one of the most important target organ injury in obesity individuals [8, 33–36] for the prevalence of obese patients [3]. Although it could even result in end-stage kidney diseases and contribute to kidney failure [37], only a few attentions were drawn from researchers and patients for its hidden process. Here, not only impaired glucose metabolism but also increased urine albumin/creatinine was measured in mice with HFD. GLP-1 level in the serum after glucose intragastric administration was decreased in HFD feeding mice. It showed that systemic GLP-1 secretions were impaired in mice with HFD. Similar findings insisted that GLP-1 analog prevents obesity-related glomerulopathy by inhibiting excessive autophagy [24]. Mice with HFD exhibited downregulated GLP-1R in the kidney. This is consistent with previous research [21]. Additionally, liraglutide, a kind of GLP-1 analog, improved the outcomes of diabetic nephropathy with similar mechanism of obesity-related glomerulopathy.

Downregulated PPAR-γ levels in renal tissue were measured in this present study. Owning to emodin is one of the ligands of PPAR-γ [38] and showed antidiabetic nephropathy effect in previous studies [39, 40]. Additionally, PPAR signaling pathway is involved in the process of obesity-related glomerulopathy [11]. So, we hypothesized that emodin may exhibit protective effect on obesity-related glomerulopathy. As far as we know, there is no report about emodin and obesity-related glomerulopathy. Therefore, emodin was used to remedy HFD-induced kidney damage. Interestingly, despite upregulated urine albumin/creatinine, downregulated GLP-1R by HFD was restored by emodin administration. Although the relationship between GLP-1R and urine albumin/creatinine is uncovered,
we focus on the regulatory mechanism of GLP-1R in this present study.

In order to investigate the regulatory mechanism of GLP-1R expression, LDL-C and palmitic acid were used to induce damage of NRK-52E cells. Although 100 μg/ml LDL-C is enough to affect the proliferation of renal tubular epithelial cells [26], in this research, 100 μg/ml or 200 μg/ml LDL-C failed to induce the downregulation of PPAR-γ and GLP-1R. This may account for oxidized cholesterol but not native cholesterol involved in the damage of renal tubular epithelial cells [41]. However, palmitic acid significantly regulated the decrement of GLP-1R and PPAR-γ of NRK-52E cells.

To clarify the effect of emodin on GLP-1R, emodin was used to treat NRK-52E cells with palmitic acid. Interestingly, decreased PPAR-γ and GLP-1R levels were reversed by emodin. GLP-1R is a kind of G protein-coupled receptor, which works by binding to ligands [42]. Additionally, its downstream second messenger signaling pathway is depending on the expression of GLP-1R. GLP-1R promoter was detected in the mixture pulled down by PPAR-γ primary antibody in a ChIP assay. It suggested the exit of interaction between PPAR-γ and promoter sequence of GLP-1R. In another word, PPAR-γ may influence the expression of GLP-1R and the downstream signaling pathway involved in injury of renal tubular epithelial cells. To verify the regulatory effect on GLP-1R expression of PPAR-γ, GW9662, a selective PPAR-γ inhibitor, was used. Amazingly, GW9662 partly abolished the recovery effect on GLP-R of emodin.

Although we have preliminarily explored the protective effect of emodin on kidney damages from HFD, there are still some limitations. Firstly, as a basic experiment, especially for an experiment that the main protein was measured by a semi-quantitative method, we failed to calculate the power for the sample size scientifically. With such a small sample basic experiment, there is a long way to clinical usage of emodin in clinical work. Secondly, emodin upregulates the levels of GLP-1R and PPAR-γ decreased in HFD mice in our experiment. However, emodin also protects individuals from weight gain, hyperglycemia, and hyperlipidemia in this work and others [43, 44]. To exclude these potential mechanisms of beneficial effect from emodin, mice with hyperglycemia were removed from this experiment. In addition, LDL-C and emodin was used to treat NRK-52E cells. However, there is still slight difference of plasma glucose of mice in each group. Moreover, other lipid levels were not considered in this work. Although body weight-matched mice in the HFD and EM-HFD groups may partly avoid the effect of weight loss effect of emodin, enough numbers of body weight-matched mice are hard to obtain. Thirdly, we used mice and rat cell line in vivo and in vitro, respectively, in this present work. The species difference may limit the scientific conclusion of this research. Fourthly, we just discussed the effect on GLP-1R expression regulated by PPAR-γ and confirm the impaired GLP-1 in serum and GLP-1R in the kidney but failed to explore the important role of GLP-1R in renal injury of obese individuals in this study. The GLP-1R knockout animal model remains needed to investigate the essential role of GLP-1R in further research.

5. Conclusion

In general, we demonstrated that emodin may alleviate the kidney damage induced by HFD via GLP-1R. Additionally, the regulation of GLP-1R may partly depend on the function of PPAR-γ activated by emodin.

Data Availability

All data used to support the findings of this study are available from the corresponding authors upon request.

Conflicts of Interest

All authors declare that the research was conducted in the absence of any commercial or financial relationships that could be construed as a potential conflict of interest.

Authors’ Contributions

Jinlei Liu and Yao Sun contributed equally to this work.

Acknowledgments

This work was partially supported by the Natural Science Foundation of Liaoning Province (No. 201602308, Bing Song).

References

[1] Collaboration NCDRF, "Worldwide trends in body-mass index, overweight, obesity from 1975 to 2016: a pooled analysis of 2416 population-based measurement studies in 128.9 million children, adolescents, and adults," Lancet, vol. 390, no. 10113, pp. 2627–2642, 2017.
[2] C. L. Ogden, M. D. Carroll, B. K. Kit, and K. M. Flegal, "Prevalence of childhood and adult obesity in the United States, 2011–2012," Journal of the American Medical Association, vol. 311, no. 8, pp. 806–814, 2014.
[3] P. Gonzalez-Muniesa, M. A. Martinez-Gonzalez, F. B. Hu et al., "Obesity," Nature Reviews. Disease Primers, vol. 3, no. 1, p. 17034, 2017.
[4] Y. Xu, L. Wang, J. He et al., "Prevalence and control of diabetes in Chinese adults," Journal of the American Medical Association, vol. 310, no. 9, pp. 948–959, 2013.
[5] L. Wang, P. Gao, M. Zhang et al., "Prevalence and ethnic pattern of diabetes and prediabetes in China in 2013," Journal of the American Medical Association, vol. 317, no. 24, pp. 2515–2523, 2017.
[6] N. Papadopoulou-Marketou, S. A. Paschou, N. Marketos, S. Adamidi, S. Adamidis, and C. Kanaka-Gantenbein, "Diabetic nephropathy in type 1 diabetes," Minerva Medica, vol. 109, no. 3, pp. 218–228, 2018.
[7] K. Tziomalos and V. G. Athyros, "Diabetic nephropathy: new risk factors and improvements in diagnosis," The Review of Diabetic Studies, vol. 12, no. 1–2, pp. 110–118, 2015.
[8] V. D’Agati, A. Chagnac, A. P. de Vries et al., "Obesity-related glomerulopathy: clinical and pathologic characteristics and pathogenesis," Nature Reviews. Nephrology, vol. 12, no. 8, pp. 453–471, 2016.
[9] E. Nehus, "Obesity and chronic kidney disease," Current Opinion in Pediatrics, vol. 30, no. 2, pp. 241–246, 2018.
Y. Li, T. Xia, R. Li, G. Tse, T. Liu, and G. Li, “Peroxisome proliferator-activated receptor delta protects against obesity-related glomerulopathy through the P38 MAPK pathway,” Obesity (Silver Spring), vol. 21, no. 3, pp. 538–545, 2013.

Z. Chen, L. Zhang, J. Yi, Z. Yang, Z. Zhang, and Z. Li, “The effects of emodin on insulin resistance in KKAy mice with diabetes mellitus,” Pharmacognosy Magazine, vol. 14, no. 56, pp. 344–350, 2018.

Y. Liu, L. Jia, Z. C. Liu et al., “Emodin ameliorates high-glucose induced mesangial p38 over-activation and hypocontractility via activation of PPARγ,” Experimental & Molecular Medicine, vol. 41, no. 9, pp. 648–655, 2009.

Y. Li, T. Xia, R. Li, G. Tse, T. Liu, and G. Li, “Renal-protective effects of the peroxisome proliferator-activated receptor-gamma agonist pioglitazone in ob/ob mice,” Medical Science Monitor, vol. 25, pp. 1582–1589, 2019.

Z. Chen, L. Zhang, J. Yi, Z. Yang, Z. Zhang, and Z. Li, “Promotion of adiponectin multiformalization by emodin: a novel AMPK activator with PPARγ-agonist activity,” Journal of Cellular Biochemistry, vol. 113, no. 11, pp. 3547–3558, 2012.

Y. Li, Q. Li, C. Wang, Z. Lou, and Q. Li, “Triglycerin reduced diabetic nephropathy and insulin resistance in type 2 diabetic rats through peroxisome proliferator-activated receptor-γ,” Experimental and Therapeutic Medicine, vol. 18, no. 2, pp. 1331–1337, 2019.

K. J. Hare, T. Vilsboll, M. Asmar, C. F. Deacon, F. K. Knop, and J. J. Holst, “The glucagonostatic and insulinotrophic effects of glucagon-like peptide 1 contribute equally to its glucose-lowering action,” Diabetologia, vol. 59, no. 7, pp. 1765–1770, 2016.

P. L. Brubaker and D. J. Drucker, “Structure-function of the glucagon receptor family of G protein-coupled receptors: the glucagon, GIP, GLP-1, and GLP-2 receptors,” Receptors & Channels, vol. 8, no. 3–4, pp. 179–188, 2002.

B. Thorens, “Expression cloning of the pancreatic beta cell receptor for the gluco-incretin hormone glucagon-like peptide 1,” Proceedings of the National Academy of Sciences of the United States of America, vol. 89, no. 18, pp. 8641–8645, 1992.

C. Wang, L. Li, S. Liu et al., “GLP-1 receptor agonist ameliorates obesity-induced chronic kidney injury by restoring renal metabolism homeostasis,” PLoS One, vol. 13, no. 3, article e0193473, 2018.

S. Ogka, K. Shikata, K. Yozai et al., “Thiazolidinedione ameliorates renal injury in experimental diabetic rats through anti-inflammatory effects mediated by inhibition of NF-κB activation,” Am J Physiol-Renal., vol. 292, no. 4, pp. F1141–F1150, 2007.

C. W. Park, Y. Zhang, X. Zhang et al., “PPAR alpha agonist fenofibrate improves diabetic nephropathy in db/db mice,” Kidney International, vol. 69, no. 9, pp. 1511–1517, 2006.

H. Guo, B. Wang, H. Li, L. Ling, J. Niu, and Y. Gu, “Glucagon-like peptide-1 analog prevents obesity-related glomerulopathy by inhibiting excessive autophagy in podocytes,” American Journal of Physiology. Renal Physiology, vol. 314, no. 2, pp. F181–F189, 2018.

Y. Ye, X. Zhong, N. Li, and T. Pan, “Protective effects of liraglutide on glomerular podocytes in obese mice by inhibiting the inflammatory factor TNF-α-mediated NF-κB and MAPK pathway,” Obesity Research & Clinical Practice, vol. 13, no. 4, pp. 385–390, 2019.

J. Li, X. Li, and H. Wang, “Human proximal tubular epithelial cells activated by low density lipoprotein promote phenotypic changes in renal interstitial fibroblasts,” Zhonghua Yi Xue Za Zhi, vol. 80, no. 10, pp. 787–791, 2000.

X. Xie, W. Yi, P. Zhang et al., “Green tea polyphenols, mimicking the effects of dietary restriction, ameliorate high-fat diet-induced kidney injury via regulating autophagy flux,” Nutrients, vol. 9, no. 5, p. 497, 2017.

F. Dou, Y. Liu, L. Liu et al., “Aloe-emodin ameliorates renal fibrosis via inhibiting PI3K/Akt/mTOR signaling pathway in vivo and in vitro,” Rejuvenation Research, vol. 22, no. 3, pp. 218–229, 2019.

J. Xiao, W. Chen, Y. Lu et al., “Crosstalk between peroxisome proliferator-activated receptor-γ and mineralocorticoid receptor in TNF-α activated renal tubular cell,” Inflammation Research, vol. 64, no. 8, pp. 603–614, 2015.

B. Song, H. Zhang, and S. Zhang, “Toll-like receptor 2 mediates deposition of collagen I in adipose tissue of high fat diet-induced obese mice,” Molecular Medicine Reports, vol. 17, no. 4, pp. 5958–5963, 2018.

H. Zhang, B. Song, and S. He, “Interleukin 29 activates expression of tissue inhibitor of metalloproteinase 1 in macrophages via Toll-like receptor 2,” Molecular Medicine Reports, vol. 17, no. 6, pp. 8363–8368, 2018.

Y. Yang, J. Ren, Y. Tong, X. Hu, Q. Lv, and N. Tong, “Protective role of PPARdelta in lipoproteinosis of pancreatic β cells,” Lipids, vol. 51, no. 11, pp. 1259–1268, 2016.

N. Kambham, G. S. Markowitz, A. M. Valeri, J. Lin, and V. D. D’Agati, “Obesity-related glomerulopathy: an emerging epidemic,” Kidney International, vol. 59, no. 4, pp. 1498–1509, 2001.

H. A. Tran, “Obesity-related glomerulopathy,” The Journal of Clinical Endocrinology and Metabolism, vol. 89, no. 12, pp. 6358, 2004.

T. Xu, Z. Sheng, and L. Yao, “Obesity-related glomerulopathy: pathogenesis, pathologic, clinical characteristics and treatment,” Frontiers in Medicine, vol. 11, no. 3, pp. 340–348, 2017.

I. M. Kutyrina, “Obesity-related glomerulopathy: mechanisms of development, clinical course,” Terapevticheskii Arkhiv, vol. 89, no. 6, pp. 97–101, 2017.

J. Tang, H. Yan, and S. Zhuang, “Inflammation and oxidative stress in obesity-related glomerulopathy,” Int J Nephrol., vol. 2012, article 608397, pp. 1–11, 2012.

J. Xue, W. Ding, and Y. Liu, “Anti-diabetic effects of emodin involved in the activation of PPARγ on high-fat diet-fed and low dose of streptozotocin-induced diabetic mice,” Fitoterapia, vol. 81, no. 3, pp. 173–177, 2010.

N. Tian, Y. Gao, X. Wang et al., “Emodin mitigates podocytes apoptosis induced by endoplasmic reticulum stress through the inhibition of the PERK pathway in diabetic nephropathy,” Drug Design, Development and Therapy, vol. 12, pp. 2195–2211, 2018.

D. Jing, H. Bai, and S. Yin, “Renoprotective effects of emodin against diabetic nephropathy in rat models are mediated via PI3K/Akt/GSK-3β and Bax/caspase-3 signaling pathways,” Experimental and Therapeutic Medicine, vol. 14, no. 5, pp. 5163–5169, 2017.
[41] C. Sastre, A. Rubio-Navarro, I. Buendia et al., “Hyperlipidemia-associated renal damage decreases Klotho expression in kidneys from ApoE knockout mice,” *PLoS One*, vol. 8, no. 12, article e83713, 2013.

[42] C. Koole, K. Pabreja, E. E. Savage et al., “Recent advances in understanding GLP-1R (glucagon-like peptide-1 receptor) function,” *Biochemical Society Transactions*, vol. 41, no. 1, pp. 172–179, 2013.

[43] J. Li, L. Ding, B. Song et al., “Emodin improves lipid and glucose metabolism in high fat diet-induced obese mice through regulating SREBP pathway,” *European Journal of Pharmacology*, vol. 770, pp. 99–109, 2016.

[44] D. Xiao, Y. Hu, Y. Fu et al., “Emodin improves glucose metabolism by targeting microRNA-20b in insulin-resistant skeletal muscle,” *Phytomedicine*, vol. 59, p. 152758, 2019.